Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy

被引:68
作者
Cheville, John C.
Karnes, R. Jeffrey
Therneau, Terry M.
Kosari, Farhad
Munz, Jan-Marie
Tillmans, Lori
Basal, Eati
Rangel, Laureano J.
Bergstralh, Eric
Kovtun, Irina V.
Savci-Heijink, C. D.
Klee, Eric W.
Vasmatzis, George [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Div Biostat, Rochester, MN 55905 USA
关键词
D O I
10.1200/JCO.2007.15.6752
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose In men who are at high-risk of prostate cancer, progression and death from cancer after radical retropubic prostatectomy (RRP), limited prognostic information is provided by established prognostic features. The objective of this study was to develop a model predictive of outcome in this group of patients. Methods Candidate genes were identified from microarray expression data from 102 laser capture microdissected prostate tissue samples. Candidates were overexpressed in tumor compared with normal prostate and more frequently in Gleason patterns 4 and 5 than in 3. A case control study of 157 high-risk patients, matched on Gleason score and stage with systemic progression or death of prostate cancer as the end point, was used to evaluate the expression of candidate genes and build a multivariate model. Tumor was collected from the highest Gleason score in paraffin-embedded blocks and the gene expression was quantified by real-time reverse transcription polymerase chain reaction. Validation of the final model was performed on a separate case-control study of 57 high-risk patients who underwent RRP. Results A model incorporating gene expression of topoisomerase-2a, cadherin-10, the fusion status based on ERG, ETV1, and ETV4 expression, and the aneuploidy status resulted in a 0.81 area under the curve (AUC) in receiver operating characteristic statistical analysis for the identification of men with systemic progression and death from high grade prostate cancer. The AUC was 0.79 in the independent validation study. Conclusion The model can identify men with high-risk prostate cancer who may benefit from more intensive postoperative follow-up and adjuvant therapies.
引用
收藏
页码:3930 / 3936
页数:7
相关论文
共 36 条
  • [1] Defining aggressive prostate cancer using a 12-gene model
    Bismar, Tarek A.
    Demichelis, Francesca
    Riva, Alberto
    Kim, Robert
    Varambally, Sooryanarayana
    He, Le
    Kutok, Jeff
    Aster, Jonathan C.
    Tang, Jeffery
    Kuefer, Rainer
    Hofer, Matthias D.
    Febbo, Phillip G.
    Chinnaiyan, Arul M.
    Rubin, Mark A.
    [J]. NEOPLASIA, 2006, 8 (01): : 59 - 68
  • [2] Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy
    Blute, ML
    Bergstralh, EJ
    Iocca, A
    Scherer, B
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2001, 165 (01) : 119 - 125
  • [3] Bostwick DG, 2000, ARCH PATHOL LAB MED, V124, P995
  • [4] DNA Topoisomerases in life and death: Implications in kinetoplastid protozoa
    Chowdhury, AR
    Majumder, HK
    [J]. CURRENT MOLECULAR MEDICINE, 2004, 4 (06) : 711 - 722
  • [5] Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells
    Davies, G
    Jiang, WG
    Mason, MD
    [J]. JOURNAL OF UROLOGY, 2000, 163 (03) : 985 - 992
  • [6] E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens
    De Marzo, AM
    Knudsen, B
    Chan-Tack, K
    Epstein, JI
    [J]. UROLOGY, 1999, 53 (04) : 707 - 713
  • [7] TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
    Demichelis, F.
    Fall, K.
    Perner, S.
    Andren, O.
    Schmidt, F.
    Setlur, S. R.
    Hoshida, Y.
    Mosquera, J-M
    Pawitan, Y.
    Lee, C.
    Adami, H-O
    Mucci, L. A.
    Kantoff, P. W.
    Andersson, S-O
    Chinnaiyan, A. M.
    Johansson, J-E
    Rubin, M. A.
    [J]. ONCOGENE, 2007, 26 (31) : 4596 - 4599
  • [8] Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens
    Epstein, JI
    Amin, M
    Boccon-Gibod, L
    Egevad, L
    Humphrey, PA
    Mikuz, G
    Newling, D
    Nilsson, S
    Sakr, W
    Srigley, JR
    Wheeler, TM
    Montironi, R
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2005, 39 : 34 - 63
  • [9] Gene expression profiling predicts clinical outcome of prostate cancer
    Glinsky, GV
    Glinskii, AB
    Stephenson, AJ
    Hoffman, RM
    Gerald, WL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) : 913 - 923
  • [10] TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer
    Hermans, Karin G.
    van Marion, Ronald
    van Dekken, Herman
    Jenster, Guido
    van Weerden, Wytske M.
    Trapman, Jan
    [J]. CANCER RESEARCH, 2006, 66 (22) : 10658 - 10663